The Common Drug Review (CDR) is currently welcoming patients to provide input to patient organizations on the manufacturer’s submission for Anakinra (Kineret) for the treatment of Still’s disease and SJIA in adults and pediatric patients aged 8 months and older with a body weight of 10 kg or above.
For this submission, the Canadian Arthritis Patient Alliance (CAPA), Cassie & Friends, and the Arthritis Society are working together to complete this submission. The survey is available for completion and will only be shared among key members of our organizations as we work together to provide feedback to the Canadian Drug Review.
The survey should take approximately 15 minutes to complete. Please submit your responses by Sunday January 3rd, 2021.
Your responses will be kept confidential and we will not disclose any identifying information.